Clinical features and outcome in North American adults with idiopathic basal arterial occlusive disease without moyamoya collaterals

Neurosurgery

Volumn 67, Issue 2, 2010, Pages 278-285

  Goyal, Manu S ^a   Hallemeier, Christopher L ^b   Zipfel, Gregory J ^a   Rich, Keith M ^a   Grubb Jr , Robert L ^a   Chicoine, Michael R ^a   Moran, Christopher J ^b   Cross, Dewitte T ^b   Dacey Jr , Ralph G ^a   Derdeyn, Colin P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Idiopathic basal arterial disease; Moyamoya

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISONE; WARFARIN;

ADULT; AGED; ANTERIOR CEREBRAL ARTERY; APHASIA; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ARTERY BYPASS; BRAIN ISCHEMIA; CEREBRAL REVASCULARIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMA; CONFUSION; DYSARTHRIA; ENCEPHALODUROARTERIOSYNANGIOSIS; FEMALE; HEADACHE; HEMIPARESIS; HUMAN; HYPERTENSION; HYPESTHESIA; IDIOPATHIC DISEASE; INTERNAL CAROTID ARTERY OCCLUSION; INTERVIEW; LETHARGY; MALE; MEDICAL RECORD REVIEW; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOYAMOYA DISEASE; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; SUPERFICIAL TEMPORAL ARTERY; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ARTERIAL OCCLUSIVE DISEASES; BASAL GANGLIA CEREBROVASCULAR DISEASE; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBRAL REVASCULARIZATION; COLLATERAL CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MOYAMOYA DISEASE; NEUROSURGICAL PROCEDURES; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 77955013765     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000371977.55753.DE     Document Type: Article

References (29)

1. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. Neuropathology. 2000;20(suppl):S61-S64.
2. Suzuki J, Kodama N. Moyamoya disease-a review. Stroke. 1983;14(1):104-109.
3. Peerless SJ. Risk factors of moyamoya disease in Canada and the USA. Clin Neurol Neurosurg. 1997;99(suppl 2):S45-S48.
4. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34-40.
5. Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke. 2001;32(10):2232-2236.
6. Meschia JF, Brott TG, Chukwudelunzu FE, Hardy J, Brown RD Jr, Meissner I, et al. Verifying the stroke-free phenotype by structured telephone interview. Stroke. 2000;31(5):1076-1080.
7. Hallemeier CL, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ, Cross DT 3rd, et al. Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke. 2006;37(6):1490-1496.
8. Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of moyamoya disease in the United States. Stroke. 1998;29(7):1347-1351.
9. Starke RM, Komotar RJ, Hickman ZL, et al. Clinical features, surgical treatment, and long-term outcome in adult patients with moyamoya disease. J Neurosurg. 2009;111(5):936-942.
10. Kraemer M, Heienbrok W, Berlit P. Moyomoya disease in Europeans. Stroke. 2008;39(12):3193-3200.
11. Ikezaki K, Han DH, Kawano T, Kinukawa N, Fukui M. A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke. 1997;28(12):2513-2517.
12. Becker VU, Eckert B, Thie A. Isolated symptomatic stenosis of the middle cerebral artery in younger adults. A clinical and ultrasonic follow-up study of eight patients. Eur Neurol. 1996;36(2):65-70.
13. Komotar RJ, Starke RM, Otten ML, et al. The efficacy of direct extracranialintracranial bypass in the treatment of symptomatic hemodynamic failure secondary to athero-occlusive disease: a systematic review. J Neurosurg. 2009;111(4):319-326.
14. Kornblihtt LI, Cocorullo S, Miranda C, Lylyk P, Heller PG, Molinas FC. Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement. Stroke. 2005;36(8):E71-E73.
15. Rodriguez GJ, Kirmani JF, Ezzeddine MA, Qureshi AI. Primary percutaneous transluminal angioplasty for early moyamoya disease. J Neuroimaging. 2007;17(1):48-53.
16. Albuquerque FC, Levy EI, Turk AS, et al. Angiographic patterns of Wingspan instent restenosis. Neurosurgery. 2008;63(1):23-27.
17. Turk AS, Levy EI, Albuquerque FC, et al. Influence of patient age and stenosis location on wingspan in-stent restenosis. AJNR Am J Neuroradiol. 2008;29(1):23-27.
18. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299.
19. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (moyamoya disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997;99(suppl 2):S238-S240.
20. Choi HY, Lee JE, Jung YH, Cho HJ, Kim DJ, Heo JH. Progression of isolated middle cerebral artery stenosis into moyamoya disease. Neurology. 2007;68(12):954.
21. Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008;39(1):42-47.
22. Mineharu Y, Liu W, Inoue K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology. 2008;70(24 pt 2):2357-2363.
23. Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR. Moyamoya disease: a summary. Neurosurg Focus. 2009;26(4):E11.
24. Hojo M, Hoshimaru M, Miyamoto S, et al. Role of transforming growth factorbeta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998;89(4):623-629.
25. Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for moyamoya disease. Neurol Med Chir (Tokyo). 2007;47(1):1-4.
26. Yamamoto M, Aoyagi M, Tajima S, et al. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke. 1997;28(9):1733-1738.
27. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27(12):2160-2165.
28. Taki W, Yonekawa Y, Kobayashi A, et al. Cerebral circulation and metabolism in adults' moyamoya disease-PET study. Acta Neurochir (Wien). 1989;100(3-4):150-154.
29. Ikezaki K, Matsushima T, Kuwabara Y, Suzuki SO, Nomura T, Fukui M. Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a perioperative positron emission tomography study. J Neurosurg. 1994;81(6):843-850.